TGF‑β signaling‑mediated immune microenvironment remodeling in urological malignancies: A contributor to immunotherapy resistance and a candidate therapeutic target (Review)

Immune checkpoint inhibitors (ICIs) have transformed the treatment of bladder cancer (BC) and renal cell carcinoma (RCC), whereas prostate cancer (PC) remains intrinsically insensitive to ICIs. In patients with BC and RCC, primary and acquired resistance remain formidable clinical challenges. Transforming growth factor‑β (TGF‑β) signaling has emerged as a contributor to immunotherapy refractoriness through its multifaceted remodeling of the tumor immune microenvironment. This pathway orchestrates CD8+ T cell exhaustion, regulatory T cell expansion, macrophage polarization toward immunosuppressive phenotypes, cancer‑associated fibroblast activation with consequent extracellular matrix remodeling, and metabolic reprogramming that sustains a tolerogenic niche. In patients with BC, PC and RCC, TGF‑β pathway activation is correlated with immune exclusion and poor responses to immune checkpoint blockade. Although TGF‑β‑targeted agents, including ligand‑neutralizing antibodies, receptor kinase inhibitors, and TGF‑β‑resistant cellular immunotherapies, have shown encouraging preclinical and early clinical activity, challenges persist regarding on‑target toxicity, the context‑dependent dual functionality of TGF‑β, and the lack of validated predictive biomarkers for patient selection. The present review comprehensively summarizes the mechanisms underlying of TGF‑β‑mediated immune evasion in urological malignancies, critically evaluates current therapeutic strategies and their limitations, and discusses emerging approaches to overcome resistance, thereby informing the rational design of TGF‑β‑targeted immunotherapies.

Authors

Institutions

Publication Details

Journal
International Journal of Oncology
Published
2026-11-20
DOI
https://doi.org/10.3892/ijo.2026.5964
Primary Topic
TGF-β signaling in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TGF‑β signaling‑mediated immune microenvironment remodeling in urological malignancies: A contributor to immunotherapy resistance and a candidate therapeutic target (Review)

Pengxiao Su, Yan Li, Xiaoke Sun
2 links
International Journal of Oncology
TGF-β signaling in diseases
article

TGF‑β signaling‑mediated immune microenvironment remodeling in urological malignancies: A contributor to immunotherapy resistance and a candidate therapeutic target (Review)

Pengxiao Su, Yan Li, Xiaoke Sun
article en

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment of bladder cancer (BC) and renal cell carcinoma (RCC), whereas prostate cancer (PC) remains intrinsically insensitive to ICIs. In patients with BC and RCC, primary and acquired resistance remain formidable clinical challenges. Transforming growth factor‑β (TGF‑β) signaling has emerged as a contributor to immunotherapy refractoriness through its multifaceted remodeling of the tumor immune microenvironment. This pathway orchestrates CD8+ T cell exhaustion, regulatory T cell expansion, macrophage polarization toward immunosuppressive phenotypes, cancer‑associated fibroblast activation with consequent extracellular matrix remodeling, and metabolic reprogramming that sustains a tolerogenic niche. In patients with BC, PC and RCC, TGF‑β pathway activation is correlated with immune exclusion and poor responses to immune checkpoint blockade. Although TGF‑β‑targeted agents, including ligand‑neutralizing antibodies, receptor kinase inhibitors, and TGF‑β‑resistant cellular immunotherapies, have shown encouraging preclinical and early clinical activity, challenges persist regarding on‑target toxicity, the context‑dependent dual functionality of TGF‑β, and the lack of validated predictive biomarkers for patient selection. The present review comprehensively summarizes the mechanisms underlying of TGF‑β‑mediated immune evasion in urological malignancies, critically evaluates current therapeutic strategies and their limitations, and discusses emerging approaches to overcome resistance, thereby informing the rational design of TGF‑β‑targeted immunotherapies.

International Journal of OncologyVol. 69(6)
Xi'an Honghui Hospital (CN), Xi'an Jiaotong University (CN)
Good health and well-being
TGF-β signaling in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
TGF‑β signaling‑mediated immune microenvironment remodeling in urological malignancies: A contributor to immunotherapy resistance and a candidate therapeutic target (Review) — Pengxiao Su, Yan Li, et al. · International Journal of Oncology (2026) | TGRS Research Map | TGRS